Skip to main content
OpenTrials
Completed

NCT Number: NCT02128204

The Safety and Efficacy of Using HYADERMIS LA for Wrinkle Correction

The study is a double-blind, randomized, within-subject controlled, 2-armed, single-centre study sponsored by SciVision Biotech Inc. and approved by Yuan's General Hospital Institutional Review Board. The aim of this post-marketing study is to evaluate the safety and efficacy of HYADERMIS LA facial dermal implant for the improvement of nasolabial folds.

The study was estimated to be held half to one year including a 0-2 weeks screening period, a day of treatment, and follow-up at week 1 and 2. Patient informed consent forms will be obtained before volunteers enter screening period. If the volunteers meet all the criteria, they will be given a number to replace their name in the study. The participants will be randomised assigned to receive experiment treatment, HYADERMIS LA, in one side of nasolabial folds and control treatment, Hya-Dermis, in the other side of the face. The safety assessment evaluated any recorded adverse events following the device treatments either by blinded evaluator or subjects. The effectiveness of the treatment devices will be assessed by using photographic assessment, nasoalabial folds severity scale, global aesthetic improvement scale, and pain visual analog scale.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pain Neurologic Manifestations Nosalabial Folds Correction Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

25 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Aesthetic Center of Yuan's General Hospital

Kaohsiung City, 80249, Taiwan

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be 25 to 60 years of age and of any sex who is willing to receive nasolabial folds correction by intradermal injection procedures
  • Have approximately symmetrical nasolabial folds with a nasolabial folds severity grade of 2-4 and the grade difference between two sides is less than 1
  • Agree to refrain from undergoing invasive aesthetic treatments in the injective areas 12 months after the injections
  • Agree to refrain from undergoing other physical or chemical aesthetic treatments in the injective areas 3 months after the injections
  • If female of child-bearing potential, not be breastfeeding, have a negative urine pregnancy test on the treatment day and agree to use any approved contraceptives or medically acceptable method of birth control throughout the study
  • Have ability to understand and comply with the study requirements, and provide the written informed consent prior to any procedures

Exclusion criteria

  • Have history or active dermal diseases, inflammation, or any related disease
  • Had permanent or semi-permanent implantation on nasolabial areas
  • Had invasive aesthetic treatments or surgeries history 6 months before the treatments
  • Had physical or chemical aesthetic treatments 1 months before the study starts
  • Have history of coagulation defect diseases and still take aspirin, anticlotting, or blood activating medications 1 week before the treatments
  • Have Adams-Stokes syndromes, wolff-prkinson-white syndromes, severe sinus node, the atrioventricular node dysfunction, or the blocked ventricular
  • Have a known history of allergic reactions like hypersensitivity to hyaluronic acid
  • Have a known history of allergic reactions like hypersensitivity to lidocaine or other anaesthetics
  • Have poor compliance with the study or follow-up schedule

Treatment and study plan

lidocaine contained hyaluronate facial dermal filler

Device

HYADERMIS LA Facial Dermal Implant contains 20 mg/ml hyaluronate and 0.3 % lidocaine.

Other names: HYADERMIS LA Facial Dermal Implant

hyaluronate facial dermal filler

Device

Hya-Dermis Facial Dermal Implant contains 20 mg/ml hyaluronate.

Other names: Hya-Dermis Facial Dermal Implant

Primary outcomes

  1. Adverse events report

    Time frame: From the date of treatment to 14 days

    Any adverse events and abnormal physical parameters or reports occurred and disappeared should be monitored throughout the trial. The records should be assessed and keep on track of the severity of individual adverse events and correlation with the treatment. Severity assessment: To assess the level of severity by rating 0 (none), 1 (mild), 2 (median), and 3 (sever). Correlation assessment: Physicians evaluate the impact of adverse events for each individual and determine their causality of the treatment, giving score 0 (no correlated), 1 (low correlated), 2 (suspected correlated), 3 (most likely correlated ). Subjects will be given a medical diary after the treatment to record any adverse event and report to a physicians. Physicians keep following up adverse events until the symptoms stabilised.

  2. Pain Visual Analog Scale

    Time frame: participants will be followed for the duration of treatment, an expected average of 10 minutes

    A quantification of the severity of pain experienced by the participants during the treatment. A scale of 100 mm horizontal line will be labeled by subjects to assess pain on both sides of the injected areas during the treatment. The one on the scale's extreme left (0) represents painless while the one on the extreme right (100) is set as the most pain could be imagined by subjects.

Secondary outcomes

  1. Nasolabial folds severity scale

    Time frame: From the baseline, 30 minutes post-treatment, and every follow-up at 1 and 2 weeks

    Based on Skin Aging Altas: Volume 2, Asian type photographs, taking gender and nasolabial folds into consideration to quantify the degree of nosalabial folds severity. A validated 8-point photographic scale scored the severity grade from 0 (absent) 7 (extreme) will be used to assess the severity.

  2. Global aesthetic improvement scale

    Time frame: 30 minutes post-treatments and follow-ups at 1 and 2 weeks

    To quantify the level of overall aesthetic improvement and so giving a scale from 1 (worse), 2 (no change), 3 (improved), and 4 (much improved), and 5 (very much improved).

  3. Pain Visual Analog Scale

    Time frame: 15, 30, 45, and 60 minutes post-treatment

    A quantification of the severity of pain experienced by the participants after the treatment. A scale of 100 mm horizontal line will be labeled by subjects to assess pain on both sides of the injected areas at 15, 30, 45, and 60 minutes post-treatment. The one on the scale's extreme left (0) represents painless while the one on the extreme right (100) is set as the most pain could be imagined by subjects.

Sponsors and collaborators

Lead sponsor

SciVision Biotech Inc.

Industry

Registry information

Important dates

Study start
2014
Primary completion
2014
Study completion
2015
First posted
May 1, 2014
Registry last updated
Jan 21, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.